Navigation Links
The concept of 'overactive bladder' serves better commercial rather than patient interests
Date:1/13/2012

"The overactive bladder syndrome has become an accepted way to simplify a complex array of symptoms and leads people to believe that an overactive bladder is an independent disease in itself. However, the truth is not as simple as this, as there are usually several factors at work explaining the symptoms. This is also one of the reasons why so called overactive bladder medications often do not bring the hoped result," says Kari Tikkinen, MD, PhD, from the HUCS Department of Urology.

The article on overactive bladder syndrome, which was co-written by Tikkinen, who currently holds a senior researcher post at the McMaster University in Canada, and Anssi Auvinen, Professor of Epidemiology from the University of Tampere, was recently published in the European Urology journal. For the article, the researchers systematically reviewed the studies on overactive bladder and the channels through which these studies have been funded.

The authors argue that the symptoms of an 'overactive bladder' ought to be studied individually and not as an ambiguous constellation of symptoms. This way the underlying causes of the symptoms can be better understood and more effective treatments can be developed.

The expression 'overactive bladder' was coined at an industry-sponsored symposium held in 1997. The following year, the FDA approved the first drug for the treatment of 'symptoms of overactive bladder', after which the pharmaceutical industry launched high-profile, worldwide promotional campaigns for drugs aimed at treatment of the syndrome.

According to the current definition, overactive bladder (OAB) syndrome is defined as the presence of urinary urgency with or without urgency incontinence, usually with increased daytime frequency and nocturia in the absence of infection or other obvious pathology.

"The definition is vague and ambiguous because it includes unspecific terms, such as 'usually' and 'with or without', and the unclear expression 'other obvious pathology'," Tikkinen says and continues, "For the pharmaceutical industry this definition is probably quite useful, as it is partly the reason why one medicine can be prescribed to a large number of patients."

Research into overactive bladder has increased significantly over the past ten years and the pharmaceutical industry has invested heavily in it. "It has previously been shown that research funded by commercial actors often ends up unpublished if the results don't serve the interests of the company," Tikkinen points out.

Tikkinen and Auvinen also bring to the fore that in many studies on prevalence of overactive bladder, very mild symptoms have been classified as abnormal.

"More independent, non-commercially funded research on the subject is needed. There are, in the end, a huge number of people who suffer from urinary urgency and increased urinary frequency, and current treatments are not bringing sufficient relief," Tikkinen says.


'/>"/>

Contact: Dr. Kari Tikkinen
kari.tikkinen@fimnet.fi
647-774-8978
University of Helsinki
Source:Eurekalert

Related medicine news :

1. Virtual Global Highlights Top Ten Misconceptions about Cloud Computing
2. The Newest Concept in Knife Sharpening
3. Organic Wholesale Club Brings Wholesale Club Concept to Large Organic and Natural E-commerce Site
4. Getting the bead on conception
5. Trek Introduces Speed Concept Triathlon Bikes
6. Donor-Assisted Conception Sparks Disclosure Dilemmas
7. Conceptualizing cancer cells as ancient toolkit
8. Winter Conception Tied to Raised Risk for Autism
9. New TB vaccine enters proof-of-concept trial in people living with HIV
10. No Proof That Aspirin Aids Conception, Review Shows
11. Magnetic attraction: NIST/CU microchip demonstrates concept of MRAM for biomolecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: